Teva: No US launch of generic Temodar during Merck & Co's appeal
This article was originally published in Scrip
Teva Pharmaceutical Industries will not launch a generic version of the cancer drug Temodar (temozolomide) any time soon despite its win earlier this year when a district court found Merck & Co's Temodar '291 patent – the only listed US patent for the brain cancer drug – unenforceable. As expected, Merck has appealed the decision, and now, Teva has announced that it has entered into an agreement pending resolution of that appeal, and will only launch its generic version if the Federal Circuit upholds the lower court finding that the Temodar patent is unenforceable.
You may also be interested in...
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.